Charles River Associates, a worldwide provider of economic, financial, and management consulting services, announced that Justus Dehnen has joined the firm as a vice president in the Life Sciences Practice based in Munich. Mr. Dehnen specializes in pricing and market access, contracting, and loss of exclusivity (LoE) strategy development projects for national and international Life Science companies.
"Justus Dehnen’s expansive background in the European life sciences industry adds depth to CRA’s European life sciences offering,” said CRA's President and Chief Executive Officer Paul Maleh. “Justus has direct industry experience, as a former CEO of an international operating biotechnology company, as well as an extensive global consulting background on pricing and market access. We look forward to offering his expertise to clients.”
Mr. Dehnen has helped life science companies to develop and maintain access, pricing, and reimbursement along the product lifecycle from early pipeline to LoE. His work extends over multiple therapeutic areas for pharma, biotech, and medical device companies. Prior to joining CRA, Mr. Dehnen was a Principal at QuintilesIMS Consulting Group where he was a member of the global Pricing and Market Access leadership team and head of the Munich office. Previously, he served as CEO of Genmedics Biotechnology and was a Senior Manager at Cell Consulting AG. Before that he was a member of the Life Science Practice at Capgemini in Paris.
He holds a Master’s degree in Corporate Management and Organization from the University of Bayreuth and completed post-graduate studies at the University of Bordeaux.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.